AN AUDIT TO DETERMINE THE SAFETY OF THE NOVEL ORAL ANTICOAGULANTS, DABIGATRAN AND RIVAROXABAN, FOR PATIENTS INITIATED ON ANTICOAGULANT THERAPY

被引：0
|
作者：
Kurunadalingam, H. [1 ]
Vizcaychipi, M. P. [1 ]
Patel, S. [1 ]
Gabriel, I. H. [2 ]
Yarranton, H. [2 ]
Morgan, D. J. Richard [3 ]
机构：
[1] Chelsea & Westminster Hosp, Anaesthesia, London, England
[2] Chelsea & Westminster Hosp, Med, London, England
[3] Chelsea & Westminster Hosp, Med & Emergency Dept Directorate, London, England
来源：
ANESTHESIA AND ANALGESIA | 2014年 / 118卷
关键词：
D O I：
暂无
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
S-216
引用
收藏
页码：S216 / S216
页数：1
相关论文
共 50 条
  • [31] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Graff, Jochen
    Harder, Sebastian
    CLINICAL PHARMACOKINETICS, 2013, 52 (04) : 243 - 254
  • [32] Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation
    Grove, Erik Lerkevang
    Skjoth, Flemming
    Nielsen, Peter Bronnum
    Christensen, Thomas Decker
    Larsen, Torben Bjerregaard
    SCIENTIFIC REPORTS, 2018, 8
  • [33] Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants
    Luger, S.
    Hohmann, C.
    Niemann, D.
    Kraft, P.
    Gunreben, I.
    Neumann-Haefelin, T.
    Kleinschnitz, C.
    Steinmetz, H.
    Foerch, C.
    Pfeilschifter, W.
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 : 277 - 277
  • [34] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Jochen Graff
    Sebastian Harder
    Clinical Pharmacokinetics, 2013, 52 : 243 - 254
  • [35] Analysis of the interaction of anticoagulants on points of care (POC) tests for urine from patients on therapy with dabigatran and rivaroxaban
    Kraemer, S.
    Giese, C.
    Du, S.
    Weiss, C.
    Harenberg, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 123 - 123
  • [36] What is the best time sampling for the two direct oral anticoagulants (DOACs), dabigatran and rivaroxaban?
    Douxfils, J.
    Baudar, J.
    Devalet, B.
    Samama, M. M.
    Chatelain, B.
    Dogne, J-M
    Mullier, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 9 - 10
  • [37] Monitoring Novel Anticoagulants Dabigatran, Rivaroxaban and Apixaban By Thrombelastography. Proof Of Concept
    Artang, Ramin
    Nielsen, Jorn Dalsgaard
    Gregg, Galloway
    BLOOD, 2013, 122 (21)
  • [38] Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
    Al-Ghafry, Maha
    Sharathkumar, Anjali
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [39] Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban
    Liotta, Eric M.
    Levasseur-Franklin, Kimberly E.
    Naidech, Andrew M.
    CURRENT OPINION IN CRITICAL CARE, 2015, 21 (02) : 127 - 133
  • [40] The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban)
    O'connor, Cormac T.
    Kiernan, Thomas J.
    Yan, Bryan P.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (07) : 725 - 739
12345